Rodney Cotton is a passionate and entrepreneurial board member, venture partner, and adviser who contributes his commercial, industry, operations, and laboratory expertise to public, private, and start-up biotech and tech-driven healthcare companies. He is known for his holistic perspective, bias for action in the face of challenges, and commitment to agile processes. Rod is currently an independent director and member of the Audit and Compensation committees of Castle Biosciences (Nasdaq: CSTL), a diagnostic testing company focused on skin cancer, gastrointestinal and mental health conditions; venture partner to 2Flo Ventures, a VC-backed healthcare and health equity accelerator; and board member of three private companies: Eisai Pharmaceuticals, a research and development pharma company specializing in neurology and oncology medicines; Moleculera Biosciences, a precision medicine company focused on immune-mediated neuropsychiatric disorders; and Orchard Software, a private equity-backed laboratory information system (LIS) software company. He is also an advisory board member to General Genomics, a predictive analytics and data curation company. Previously, Rod built a robust career at Roche Diagnostics, the North American headquarters of the world's largest ($17B) diagnostics company, that spanned more than two decades and culminated in the role of SVP, Head of Strategy & Transformation, and Chief of Staff to the CEO. With 40+ years of executive experience, Rod drove the financial turnaround and cultural transformation of four global healthcare companies, led teams of up to 280 total reports, and managed P&L of more than $1 billion. He also served as a key member of the senior leadership team executing Roche’s most significant restructuring in two decades and led key enterprise initiatives for the $4B company, such as milestone corporate communications, health equity coalitions, the US/Roche Group audit, and global/US acquisition integrations. In the face of the COVID-19 pandemic, Rod and his team at Roche accelerated six ground-breaking products in 11 months, including the first launch of the market's most accurate and in-demand molecular diagnostic test. He also solved extraordinary challenges of product scarcity, supply chain, product allocation, and logistics to achieve accelerated global sourcing and self-manufacturing in line with testing guidelines. A frequent public speaker, Rod was named among the Most Influential Corporate Directors and Most Influential Black Executives in Corporate America by Savoy Magazine, Top Blacks in Healthcare by BlackDoctor.org, and 100 Black Board Members Making a Difference by BoardProspects. He received The Sagamore of the Wabash Award, one of the highest Indiana State honors, bestowed by Indiana Governor Eric J. Holcomb. Rod holds an M.B.A. from California State University, Dominguez Hills, an M.S. in Strategic Management from the University of Southern California, and a B.A. in Biological Sciences & Technology from the University of California at Santa Barbara. He has also attended the M&A Executive Program at Harvard Business School and the Director’s Consortium Executive Program at Stanford Graduate School of Business.